Paxlovid Antiviral

 Effective April 12, 2022 

The ministry has worked with the Chief Medical Officer of Health, Ontario Health, and the Science Advisory Table to provide clinical guidance as to which patients will best benefit from treatment with Paxlovid™.

The clinical criteria are that:

1. The individual has received a positive COVID-19 test result; and

2. The individual will be starting Paxlovid™ treatment within 5 days of symptom onset; and

3. One of the following factors applies to the individual:

• The individual is 18 years of age or older and is immunocompromised;
• The individual is 70 years of age or older;
• The individual is 60 years of age or older and has received less than three doses of a COVID-19 vaccine;
• The individual is 18 years of age or older, has received less than three doses of COVID-19 vaccine, and has at least one of the following risk conditions:
  • obesity
  • diabetes
  • heart disease
  • chronic respiratory disease (including cystic fibrosis
  • cerebral palsy
  • intellectual and develepmental disease
  • sickle cell disease
  • moderate or severe kidney disease
  • moderate of severe liver disease
  • pregnant and unvaccinated (zero doses)

4. The individual is assessed as being at higher risk of severe COVID-19 based on their age, vaccination status, and risk conditions (excluding risks due to travel) by their prescriber.

For more information on COVID-19 antiviral treatment, please click HERE